The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: (link sends e-mail)

Study Name on (link is external)
Extention Study of ArikaceTM in CF Patients With Chronic Pseudomonas Aeruginosa Infection
Study DrugArikaceTM (Liposomal amikacin for inhalation)
Type of Study DrugAnti-infective
Study TitleLong Term Safety and Tolerability of Open-Label Liposomal Amikacin for Inhalation (ArikaceTM) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Study Phase3
Study SponsorInsmed

Link on (link is external) (link is external)

Participating ECFS-CTN sitesBelgium: Leuven
Denmark: Copenhagen
UK: London, Birmingham, Nottingham
Germany: Berlin, Frankfurt
Spain: Barcelona
Italy: Verona
France: West-Paris (Cochin)
Age6 years and older